Previous Article | Next Article ![]()
Journal of Clinical Microbiology, November 2001, p. 3942-3945, Vol. 39, No. 11
Department of Pediatrics, Columbia
University, New York, New York
Received 29 June 2001/Returned for modification 7 August
2001/Accepted 21 August 2001
In the past decade, potential pathogens, including
Alcaligenes species, have been increasingly recovered from
cystic fibrosis (CF) patients. Accurate identification of multiply
antibiotic-resistant gram-negative bacilli is critical to understanding
the epidemiology and clinical implications of emerging pathogens in CF.
We examined the frequency of correct identification of
Alcaligenes spp. by microbiology laboratories affiliated
with American CF patient care centers. Selective media, an
exotoxin A probe for Pseudomonas aeruginosa,
and a commercial identification assay, API 20 NE, were used for
identification. The activity of antimicrobial agents against these
clinical isolates was determined. A total of 106 strains from 78 patients from 49 CF centers in 22 states were studied. Most (89%) were
correctly identified by the referring laboratories as Alcaligenes
xylosoxidans. However, 12 (11%) strains were
misidentified; these were found to be P. aeruginosa
(n = 10), Stenotrophomonas maltophilia
(n = 1), and Burkholderia cepacia (n = 1). Minocycline, imipenem, meropenem,
piperacillin, and piperacillin-tazobactam were the most active since
51, 59, 51, 50, and 55% of strains, respectively, were inhibited. High
concentrations of colistin (100 and 200 µg/ml) inhibited 92% of
strains. Chloramphenicol paired with minocycline and ciprofloxacin
paired with either imipenem or meropenem were the most active
combinations and inhibited 40 and 32%, respectively, of strains.
Selective media and biochemical identification proved to be useful
strategies for distinguishing A. xylosoxidans from other CF
pathogens. Standards for processing CF specimens should be developed,
and the optimal method for antimicrobial susceptibility testing of
A. xylosoxidans should be determined.
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.11.3942-3945.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Identification and Antimicrobial Susceptibility of
Alcaligenes xylosoxidans Isolated from Patients with
Cystic Fibrosis
*
Corresponding author. Mailing address: Columbia
University, 650 West 168th St., PH 4 West Rm. 470, New York, NY 10032. Phone: (212) 305-9446. Fax: (212) 305-9491. E-mail:
LS5{at}columbia.edu.
Present address: Department of Laboratories, Meridian Health
System, Neptune, N.J.
This article has been cited by other articles:
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|